Skip to content

Effect of Different Concentrations of Sevoflurane for Anesthesia Induction in Pediatric Ophthalmic Surgery

Effectiveness and Safety of 6% Versus 8% Sevoflurane for Anesthesia Induction in Pediatric Ophthalmic Minor Surgery: A Randomized Controlled Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07450495
Acronym
SEVO-PED
Enrollment
80
Registered
2026-03-04
Start date
2025-02-25
Completion date
2026-02-26
Last updated
2026-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chalazion

Brief summary

This randomized controlled trial aims to compare the effectiveness and safety of 6% versus 8% sevoflurane inhalation induction in pediatric patients undergoing minor ophthalmic surgery. The primary outcome is emergence agitation assessed using the Pediatric Anesthesia Emergence Delirium (PAED) scale. Secondary outcomes include hemodynamic parameters, induction time, recovery time, and adverse events.

Interventions

DRUGSevoflurane

Sevoflurane inhalation anesthesia was used for induction and maintenance of general anesthesia in pediatric patients undergoing minor ophthalmic surgery.

Sponsors

Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
1 Years to 6 Years
Healthy volunteers
No

Inclusion criteria

* Children aged 1 to 6 years (12-72 months) * Scheduled to undergo minor ophthalmic surgery (e.g., chalazion excision) under general anesthesia * American Society of Anesthesiologists (ASA) physical status I * Assessed as suitable for inhalation anesthesia by anesthesiologists * Written informed consent obtained from parents or legal guardians

Exclusion criteria

* ASA physical status II or higher * Known hepatic or renal dysfunction * Congenital heart disease * History of malignant hyperthermia * Known allergy to sevoflurane * History of asthma or severe respiratory disease * Upper respiratory tract infection within the past 4 weeks * Anticipated difficult airway * Refusal of participation by parents or legal guardians

Design outcomes

Primary

MeasureTime frameDescription
PAED scoreWithin 30 minutes after recoveryMeasured using the Pediatric Anesthesia Emergence Delirium (PAED) scale. The PAED scale ranges from 0 to 20, with higher scores indicating more severe emergence delirium (worse outcome).

Secondary

MeasureTime frameDescription
Induction timeImmediately after anesthesia inductionTime from face mask placement to loss of eyelash reflex, measured in seconds.
Recovery timeImmediately after anesthesia discontinuationTime from discontinuation of sevoflurane to full recovery of consciousness, measured in minutes.
Minimum alveolar concentration (MAC)PerioperativelyMinimum alveolar concentration (MAC) values recorded during anesthesia maintenance.
Respiratory depressionPerioperativelyIncidence of respiratory depression recorded during the perioperative period.
HypoxiaPerioperativelyIncidence of hypoxia recorded during the perioperative period.
CoughPerioperativelyIncidence of cough recorded during the perioperative period.
Nausea and vomitingImmediately after anesthesia until dischargeIncidence of nausea and vomiting recorded during the postoperative recovery period.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 26, 2026